Last reviewed · How we verify
rabbit ATG（Sanofi/Genzyme）
Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering immune-mediated destruction.
Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering immune-mediated destruction. Used for Prevention of acute rejection in renal transplantation, Treatment of acute rejection in renal and other solid organ transplants, Aplastic anemia (severe).
At a glance
| Generic name | rabbit ATG（Sanofi/Genzyme） |
|---|---|
| Also known as | Thymoglobuline |
| Sponsor | Chinese PLA General Hospital |
| Drug class | Polyclonal antithymocyte globulin (ATG) |
| Target | Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR, and others) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Transplantation |
| Phase | FDA-approved |
Mechanism of action
Rabbit ATG is derived from immunizing rabbits with human T lymphocytes, producing polyclonal antibodies against multiple T-cell surface antigens. These antibodies bind to circulating and tissue-resident T cells, leading to their elimination through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and opsonization. This profound T-cell depletion suppresses cell-mediated immunity and is used to prevent or treat rejection in transplantation and certain autoimmune conditions.
Approved indications
- Prevention of acute rejection in renal transplantation
- Treatment of acute rejection in renal and other solid organ transplants
- Aplastic anemia (severe)
Common side effects
- Cytokine release syndrome (fever, chills, malaise)
- Leukopenia and thrombocytopenia
- Infection (opportunistic and bacterial)
- Serum sickness
- Thrombophlebitis at infusion site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rabbit ATG（Sanofi/Genzyme） CI brief — competitive landscape report
- rabbit ATG（Sanofi/Genzyme） updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI